Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
anyone that has $50,000.00 bucks would not put it all in one stock, he must of ment 50,000 shares thats just commen since?
SEEK AND YOU WILL FIND $$$$$$$
AMBS we all know big profits for share holders, and the best news is for the hurt, and the cure
I feel not if but when, this will take us to the bank$$$$$ soon 60 or 90 days,
gold, we will head north, this is a healthy pull back if you go to fast north you will go fast south , even though it is fun to go north fast, but this should take us to the bank in a fair time.$$$$$$$$$$$
Redcuffs,
You as well as me know they have offers on the table, but you dont make a answer to the offer untell you get the best offer, ther is moast likely a bidding war , this stock will hit $1.00 to $10.00 once the deal is made on a buyout.
and be honest if you flip or short its all leagal,but just be honest so there is no confuision, thanks buddy and good luck.
to all shortes, you are in it to win it and it is legal, but you all know AMBS has a new team, that is part of the up grade on OTC this will not allow massive shorting, and according to Scottstrade there will be a money amount on a stock to keep the new tier for ambs, there is a 360 change about to happen, big, BIG things are going to make us $$$$ and retire sooner than some, just so hard to belive this is happening in front of our eyes, so awsome, aswome.
called scootrade, they told me that the upgrade to the OTC is way better that the otc/finra /bb= bulitin board, and there is a stock price minimum to be on the OTC, we are in great hands, big mony to come, this is a step, up , after OTC it will become NASDAQ
However i dont know the minimum price to be on the OTC forgot to ask but way better that otcbb, yes.
we are going to start moving.
Heavily Promoted Penny Stocks For April 20
ADVERTISEMENT
NewsletterDETAILS 'JUNP -News Alert' Apr 09, 2011 19:05 Promoter: NewStockIdea Paying Party: UNKNOWN
Stocks covered: Compensation: Avg $ Volume for Period:
JUNP $5000 13614
Max Profit: 50.00 % Gain at close: 0.00 %
*We think that this promoter is a part of a group of promoters.
Watch the video to learn about the probability of Juniper Group, Inc. (JUNP) Chart Signal as of Apr 26 2013 Hotstocked Precision will calculate the probabilities of Juniper Group, Inc. (JUNP)
Rating:
Size: 656KB
Version: 1.1
Platform: Win/Mac
Downloads: 368,836
FREE DOWNLOAD
Our Weekend Special New Stock Idea alert is - JUNP
Our alerts this week QEDN and GDHI traded record volume this week. Keep watching those for more movement.
JUNP is as a trading at lows not seen in a while and popped upwards of more than 300% up over the .001 mark not long ago.
Everyone should keep an eye on this one. Could move once again and is trading daily.
JUNP Just released News on working with a major Cable provider.
http://finance.yahoo.com/news/Juniper-Expands-Cable-pz-2374410598.html?x=0&.v=1
"Juniper Expands Cable Initiative With Cable Industry Leader"
JUNP - Juniper Group- http://www.junipergroup.com/
This could be the start of a big run for JUNP with possible bigger things to come.
Stocks at this level can be very risky so do your research.
Juniper Group Inc., through its subsidiaries, provides wireless infrastructure services primarily in the Eastern and Central United States. Its wireless infrastructure services consists of wireless and cable broadband installation services on a regional basis by providing broadband connectivity services for wireless and cable service providers. The company offers site surveys, tower construction, and antenna installation, tower system integration, and hardware and software installations for telecommunication companies; and site acquisitions and co-location facilitation services, as well as maintains and upgrades wireless telecommunication network sites. In addition, it engages in the sale or exploitation of film licenses. The company was founded in 1987 and is headquartered in Boca Raton, Florida.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
PLEASE NOTE WELL: The thenewstockidea.com employees are not Registered as an Investment Advisor in any jurisdiction whatsoever.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Many times we are compensated to feature companies on our site which causes a conflict in interest.
Release of Liability: Through use of this website viewing or using you agree to hold thenewstockidea .com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur.
thenewstockidea.com is owned by wind and sea Inc. is written and published by thenewstockidea.com and windandseainc.com . Readers are advised that this analysis report is issued solely for informational purposes. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. . They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. thenewstockidea .com encourages readers and investors to supplement the information in these reports with independent research and other professional advice.
As with any business, your results may vary, and will be based on your background, dedication, desire and motivation. We make no guarantees regarding the level of success you may experience. You may also experience unknown or unforeseeable risks which can reduce results. We are not responsible for your actions.
All information on featured companies is provided by the companies profiled, or is available from public sources and thenewstockidea com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. thenewstockidea .com, nor any of its affiliates are not registered investment advisors or a broker dealers. thenewstockidea .com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor’s sole risk. thenewstockidea .com has also been advised that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s entire investment may be lost or impaired due to the speculative nature of the companies profiled.v.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through thenewstockidea .com. thenewstockidea .com owners may or may thenewstockidea ot hold positions in the companies that are profiled. Investing in securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. NewStockidea.com expects to recieve five thousand dollars from a third party on profile of JUNP.
Third Party Web Sites and Information thenewstockidea .com and newsletter may provide hyperlinks to third party websites or access to third party content. thenewstockidea .com does not control, endorse, or guarantee content found in such sites. You agree that thenewstockidea .com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that thenewstockidea .com, Inc. shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
le2dynasty we will go north soon, any info out there att 4g ect
Benosufan, show me a legal doc that sayes there will be a RS, then i could belive, outher than that we are headed in the right direction, thanks
from what i understand is the company that buys us out will have a highr pps if they are 20cents we will blend to a higher pps, not lower, somthing big may happen soon, ther is NOTHING that sates a RS if it did, please poast it outher that that it is in our favor, IMO, let make some profit my frinds. lets roll.
Is amgn going to by out AMBS rumers, any ifo please pass on thanks
what do you think will happen to the pps in the next 90 days?
Oils,
slow volume, but not dead, there is still a pulse, soon we will prosper.
hopfully we get news soon, come on JUNP, lets get rolling
thanks for the post Lask
Also i need not to post every day, I know what i owne.
GLTA
AMB$ long for over 3 months.
some peaple are shorters BH
monday morning , huge news hopfully, just hoping lets roll people, thanks.
i have owned this stock forever, but have not followed it, so in a nut shell can i be updated, in easy english, pleas, thanks
biggest move we had in some time,a large fire starts with a spark, any info out there?
small movement, but need alot more and news
some one keeps chipping away any word on junp?
Here you are blackhawks
Quote:
--------------------------------------------------------------------------------
Lewis Sogge <>
Feb 18 (2 days ago)
to gerald
Gerald,
Just wanted to make sure you were aware of this breaking news story which I believe could potentially impact Amarantus in a huge way...
www.nytimes.com/2013/02/18/science/project-seeks-to-build-map-of-human-brain.html?pagewanted=1&_r=0&hp
The goals of this initiative are surprisingly similar to those of AMBS. This paragraph was the most exciting for me for obvious reasons:
"Scientists with the highest hopes for the project also see it as a way to develop the technology essential to understanding diseases like Alzheimer’s and Parkinson’s, as well as to find new therapies for a variety of mental illnesses."
Bests,
Lewis Sogge
Gerald Commissiong via sogge.com
6:45 PM (1 hour ago)
to lew
Hi Lewis,
I will be in DC March 6 and 7th. Will that work to get a group together?
Best Regards,
Gerald
Gerald E. Commissiong
President & CEO
Amarantus Bioscience, Inc.
OTCQB: AMBS
America runs on dunkindonuts,
You are right, jv or a possable buy out on the bloodtest $$$$$$
4 more trading days for big conferice in DC, where he is working to get a JV / team put togather , we will see dollar land this year , sooner than later
JEM-BERLIN. are you wone of the Berlin boys who can buy anymore?
Jst curious?
So do the Berlin boys still owne ther shares an if so can they still sell them, and if they can i am sure they are now long, your thoughts, nice to see all the scamers off this board also.
HUGE THINGS TO COME $$$$$$$$$$$$$$
Amarantus BioScience (AMBS) To Be Biotech Stock Of 2013_Acquisition Discussions Already Underway Projects Biotech News Stock Review
Amarantus BioScience (AMBS) To Be Biotech Stock Of 2013_Acquisition Discussions Already Underway Projects Biotech News Stock Review.
Adam believes that he has found the golden egg, AMBS. He may very well be correct, what I'm hearing is that buyout discussions are already happening between this small biotech and a big pharmaceutical. I'm working my sources but things are pretty hush hush with NDA's having to be signed. Adam may be correct and AMBS could certainly become the biotech stock of the year.
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was fundamental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing.
Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts.
If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.
Posted by Sierra World Equity Review at 1:05 AM
you keep yelling, please stop, if you do your reaserch/DD you would see he is in DC next week for his JV? buyout , we are solid, if you are a shorter or flipper, you may be left out , most of the float is locked up , just a few mm amd flippers trying ther best to survive, but short lived, please do your DD
he told us he will have a new team next week? think about it DC team AMBS will move to the next level
DR JErry, i need to know were you stand, and how do you know info before AMBS puts it out, it confuses me, however i am long with AMBS blease explane and if you are right expane what we should expect$$ ect, i can not do a personal post only a all out due to my account, but you can send me a personal message and i will git it, thank you dr jerry.
LEWSOGGE,
I AM A LITTLE CONCERNED ABOUNT DR Jerry, have not heard from him he made clames about MJF not proviging funds before the company tells us is he a pumper, i had respect for him, but he disipeared? whats your thought? any one can be any one, i could be a docter a wife a husband or a 12 year old boy/girl, is he for real or just a puper, I HOP HE IS REAL.
lock in you shares, big money monday, the train in heading out to $$$$ land, do your DD , retirment for some in the nex 90 days imo .
solantey, that is why they use the "form 4" to inform when a company purches shares or sells,
pipline
Amarantus BioScience (AMBS)_Accumulation At Low Levels Prior To Acquisition_Pfizer (PFE) M&A Team at Headquarters Projects Biotech News Stock Review
Amarantus BioScience (AMBS)_Accumulation At Low Levels Prior To Acquisition_Pfizer (PFE) M&A Team at Headquarters Projects Biotech News Stock Review.
Johnny believes that the talented merger and acquisition team of Pfizer will be meeting with AMBS in New York in the first week of February. Potential for a buyout or a joint venture, either way look for official news coming.
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was fundamental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing.
Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts.
If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.
Posted by Sierra World Equity Review at 11:03 PM Email ThisBlogThis!Share to TwitterShare to Facebook
Newer Post Older Post Home Popular Posts
Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review
Pfizer (PFE) Talking To Bio-Matrix Scientific (BMSN) In NYC This Week Forecasts Biotech News Stock Review
Part ONE:Biotech Stock Share Price Rise Or Fall Projections For Week Of February 19th To February 22nd 2013
A Fly On The Wall_Eisai, Roche And Arena Pharmaceuticals (ARNA) Conference Call_Partnership In EU With EMA Belviq Approval Topic Projects Biotech News Stock Review
Amarantus BioScience (AMBS)_Accumulation At Low Levels Prior To Acquisition_Pfizer (PFE) M&A Team at Headquarters Projects Biotech News Stock Review
Bio-Matrix Scientific Group (BMSN) Buyout Discussions Advanced Projects Biotech News Stock Review
Fledgling Bio-Matrix Scientific (BMSN) And Big Pharma Pfizer (PFE) Look To Unite Projects Biotech News Stock Review
Don't Panic_Biotech News Stock Review Called It_Bio-Matrix Scientific (BMSN) Falls But Will Rebound Forecasts Adam And Johnny
Bio-Matrix Scientific Group (BMSN) To Hit 10 Cents In Two Months Forecasts Biotech News Stock Review
Keryx Biopharmaceuticals (KERX) and GlaxoSmithKline (GSK) move closer on acquisition!
Blog Archive
? 2013 (51)
? February (15)
? January (36)
Peregrine Pharmaceuticals (PPHM) To Surprise Share...
Pfizer (PFE) Shows Renewed Interest In Arena Pharm...
Roche Talking To Bio-Matrix Scientific Group (BMSN...
Keryx Biopharmaceuticals (KERX) & GlaxoSmithKline ...
Biotech News Stock Review Called It First_Amarantu...
Adam and Johnny Called It_Keryx Biopharmaceuticals...
Breaking....Pfizer (PFE) BOD Straw Poll Unanimous ...
Biotech News Stock Review Calls It First! Anacor P...
Adam & Johnny Make The Call_Bio-Matrix Scientific ...
Celsion (CLSN) To Rise 200% To Target Price Of $23...
ACADIA Pharmaceuticals (ACAD) Epic Run Coming_Pric...
Bio-Matrix Scientific Group (BMSN) Price Target $1...
Amarantus BioScience (AMBS) To Be Biotech Stock Of...
A Fly On The Wall_Eisai, Roche And Arena Pharmaceu...
Epic Run To Begin For Hemispherx Biopharma (HEB)_F...
Roche To Step In To New Partnership Role With Aren...
Keryx Biopharmaceuticals (KERX) Positive Data For ...
Amarantus BioScience (AMBS) Target Price After Pot...
Biotech News Stock Review Best Stock Buys For Wedn...
Bio-Matrix Scientific (BMSN) Break Out Imminent_Of...
Keryx Biopharmaceuticals (KERX) Buyout Interest Fr...
Amarantus BioScience (AMBS)_Accumulation At Low Le...
Bio-Matrix Scientific Group (BMSN) Poised To Annou...
Amarantus BioScience (AMBS) To Be Among The First ...
Dendreon (DNDN) Pipeline Drug Provenge Yields Posi...
Cell Therapeutics (CTIC) To Shine In 2013 As Big P...
BioSante Pharmaceuticals (BPAX) Oversold_Big Bounc...
Aeterna Zentaris (AEZS) Price Target $7 By 4th Qua...
Keryx Biopharmaceuticals (KERX) Positive Top Line ...
Peregrine Pharmaceuticals (PPHM) Pipeline Drug Bav...
VIVUS (VVUS) To Rebound Over $25 By The End Of Mar...
Alexza Pharmaceuticals (ALXA) New Murmurs_An Acqui...
Bio-Matrix Scientific Group (BMSN) To Hit 10 Cents...
Amarantus BioScience (AMBS) Price Target $2.25 By ...
Arena Pharmaceuticals (ARNA) Entrance Points for t...
Biotech News Stock Review_Top 5 Biotech Stocks For...
Disclaimer and Privacy Policy
DISCLAIMER:
This blog is for fictional and entertainment purposes only! Best Penny Stocks Review and it's publisher, do not accept payment to feature or recommend any stock. Nobody knows about our stock picks before they are published live on the Blog. We are not affiliated with any executives, owners, brokers, promoters or trading groups.The publisher is not a registered investment adviser. Readers and subscribers should not view information found within this domain as offering personalized, legal, tax, accounting, stock or investment-related advice. Viewpoints, information, entertainment and fictional posts presented within this blog are our own, accuracy is not guaranteed. Any hyper-links listed on this site that link back to any other web sites are not to be construed as an endorsement by us of that particular site, its products, or its contents. Hyper-links to other sites should be visited at your own risk. All materials presented on this web site are not to be regarded as investment advice and are only offered for fictional and entertainment purposes. Before making a purchase or sale of any securities featured on this site, we strongly recommend consultation with a registered securities representative. This blog is not to be construed as a solicitation to buy or sell securities. Any stock pick recommendation or companies selected or presented involve a high degree of investment risk and volatility. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any stock picks presented within this web site. Penny stocks, small cap stocks, mid cap stocks should be viewed as very high-risk speculations. It should be understood that there is no guarantee that past performance will be indicative of future results. The accuracy, information or completeness of the picks posted on this blog is for fictional and entertainment purposes only! We do not guarantee that any or all of our stock picks will ever increase in value (share price) at any particular time after the pick goes live on the blog since all stocks can decrease in value at any time. It is your decision alone to buy or sell any stock presented on this site. All characters ever mentioned and presented by the publisher in this blog are fictional characters and all posts in the blog should be construed as being for fictional and entertainment purposes only! Safe Harbor Disclosure: The information and services contained within this site may include or incorporate by reference “forward looking statements” including certain information with respect to plans and strategies of featured companies. For this purpose, any statements on the site or incorporated by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting or forgoing the words “should”, “could”, “may” “believe”, “anticipate”, “plan”, "ventures", “expect”, “project” and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks, uncertainties, and assumptions about each company, economic and market factors in industries in which the companies do business, among other factors. These statements are in no way guarantees of future performances and actual events, and results may differ materially from those expressed or forecasted by the companies due to many factors. For further information about securities and their regulation, visit the site of the Securities and Exchange Commission (SEC) at www.sec.gov
PRIVACY POLICY:
What information do we collect? We collect information from you when you register on our site or subscribe to our newsletter. When ordering or registering on our site, as appropriate, you may be asked to enter your: e-mail address. You may, however, visit our site anonymously. Google, as a third party vendor, uses cookies to serve ads on your site. Google's use of the DART cookie enables it to serve ads to your users based on their visit to your sites and other sites on the Internet. Users may opt out of the use of the DART cookie by visiting the Google ad and content network privacy policy.. What do we use your information for? Any of the information we collect from you may be used in one of the following ways: -To send periodic emails The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions. Do we use cookies? Yes (Cookies are small files that a site or its service provider transfers to your computers hard drive through your Web browser (if you allow) that enables the sites or service providers systems to recognize your browser and capture and remember certain information We use cookies to compile aggregate data about site traffic and site interaction so that we can offer better site experiences and tools in the future. Do we disclose any information to outside parties? We do not sell, trade, or otherwise transfer to outside parties your personally identifiable information. This does not include trusted third parties who assist us in operating our website, conducting our business, or servicing you, so long as those parties agree to keep this information confidential. We may also release your information when we believe release is appropriate to comply with the law, enforce our site policies, or protect ours or others rights, property, or safety. However, non-personally identifiable visitor information may be provided to other parties for marketing, advertising, or other uses. Third party links Occasionally, at our discretion, we may include or offer third party products or services on our website. These third party sites have separate and independent privacy policies. We therefore have no responsibility or liability for the content and activities of these linked sites. Nonetheless, we seek to protect the integrity of our site and welcome any feedback about these sites. California Online Privacy Protection Act Compliance Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent. Childrens Online Privacy Protection Act Compliance We are in compliance with the requirements of COPPA (Childrens Online Privacy Protection Act), we do not collect any information from anyone under 13 years of age. Our website, products and services are all directed to people who are at least 13 years old or older. Your Consent By using our site, you consent to our privacy policy. Changes to our Privacy Policy If we decide to change our privacy policy, we will post those changes on this page.
Simple template. Powered by Blogger.
28e42f44-c674-4abf-9b80-e64a2c399fbc
Y2:28e42f44-c674-4abf-9b80-e64a2c399fbc
Related Searches:Preferred Shares|Information On Stock Trading|Stock Market News|Top Stock Picks|ETF Investing|Trading Stocks|Biotechnology News|Top Penny Stocks|Free Real Time Stock Quote|Online Trading|Biotechnology Stocks|
gray area long now , i new you were long for ambs, just takes a little time, you rock and wait tell monday weeeeeeeeee
Biotech News Stock Review
Thursday, January 24, 2013Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review.
Adam crunched the numbers and it looks very impressive for AMBS if Pfizer purchases them. The first week of February could be very exciting for AMBS shareholders as we believe that PFE is meeting with AMBS in NYC, watch for official press releases around that time frame.
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was fundamental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing.
Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts.
If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about.
Posted by Sierra World Equity Review at 12:57 AM
Amarantus BioScience (AMBS) Target Price After Potential Pfizer (PFE) Acquisition $2.70 Projects Biotech News Stock Review.
Adam crunched the numbers and it looks very impressive for AMBS if Pfizer purchases them. The first week of February could be very exciting for AMBS shareholders as we believe that PFE is meeting with AMBS in NYC, watch for official press releases around that time frame.
time frame February, 30 days.
If I was a shorter or a flipper i would feel the same, im sure many peaople made lots of $$ that way i wish i held that talent good luck to you , but for me i cant take that risk at this point, to close to a deal whats your thought?
Thats not correct, I know for a fact things are happening behind doors march first week, a team is coming together, for AMBS, better hold your shares, he is in DC that week, HUGE thangs to come a buy out could be $2.70 to $400 a share just for the test kit and possable $20.00 for MANF, per share trust me and do you DD,
KNOW WHAT YOU OWNE, and dont let people take your shares.
big thing are soon to happen, a majority of the float is locked up only MM and shortes and a few flippers left when the JV or buy out is annouced everyone who dont own shars will be loced out at that $2.70 min buy out, please read this part is from lewsogge if i spelt his name right
from Gerald:
Quote:
--------------------------------------------------------------------------------
Lewis Sogge <>
Feb 18 (2 days ago)
to gerald
Gerald,
Just wanted to make sure you were aware of this breaking news story which I believe could potentially impact Amarantus in a huge way...
www.nytimes.com/2013/02/18/science/project-seeks-to-build-map-of-human-brain.html?pagewanted=1&_r=0&hp
The goals of this initiative are surprisingly similar to those of AMBS. This paragraph was the most exciting for me for obvious reasons:
"Scientists with the highest hopes for the project also see it as a way to develop the technology essential to understanding diseases like Alzheimer’s and Parkinson’s, as well as to find new therapies for a variety of mental illnesses."
Bests,
Lewis Sogge
Gerald Commissiong via sogge.com
6:45 PM (1 hour ago)
to lew
Hi Lewis,
I will be in DC March 6 and 7th. Will that work to get a group together?
Best Regards,
Gerald
Gerald E. Commissiong
President & CEO
Amarantus Bioscience, Inc.
OTCQB: AMBS
--------------------------------------------------------------------------------